Abstract
Objective Long-term opioid use is associated with diminished pain relief, hyperalgesia, and addiction which is not well understood. This study aimed to characterise opioid-related brain network alterations in chronic pain, focused on the right amygdala, and left mediodorsal thalamic nuclei that play key roles in affective pain processing, and are particularly rich in mu opioid receptors (MOR).
Subjects Participants on opioid prescriptions with painful knee osteoarthritis and matched non-opioid using control pain participants.
Methods and design Seed-based functional connectivity (FC) maps from resting-state fMRI data were compared between groups.
Results We found right amygdala hyperconnectivity with the posterior default mode network (pDMN) and the dorsomedial prefrontal cortex in opioid users in contrast to anti-correlations in controls. Conversely, opioid users showed predominant hypoconnectivity of the left dorsomedial thalamic seed with the cingulate cortex except for the subgenual part displaying an anti-correlation in opioid users and no association in non-users. Opioid users also showed higher negative affect in exploratory post-hoc tests suggesting a potential contribution of trait anxiety to amygdala-pDMN FC alteration.
Conclusion Opioid use related hyperconnectivity of the right amygdalar network likely reflects maladaptive mechanisms involving negative affect and network plasticity. Hypoconnectivity of the mediodorsal thalamic nuclei with the anterior and mid cingulate on the other hand may reflect impaired resilience in line with previously reported compensatory MOR upregulation. In conclusion, this study provides new insight into possible brain mechanisms underlying adverse effects of prolonged opioids in chronic pain and offer candidate network targets for novel interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We are grateful to Versus Arthritis for providing financial support (Grant 20777). AT received PhD scholarship support from the Haydn Green Foundation and AMN is supported by the NIHR Nottingham Biomedical Research Centre.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by NRES Committee East Midlands - Nottingham 2 (REC reference number: 10/H0408/115).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: We are grateful to Versus Arthritis for providing financial support (Grant 20777). AT received PhD scholarship support from the Haydn Green Foundation and AMN is supported by the NIHR Nottingham Biomedical Research Centre.
There are no conflicts of interest or disclosures from any co-author.
2 Level ranges from 8: none to 1: higher degree, postgraduate degree. See supplementary for more details.
Data Availability
Data used in this study may be available upon reasonable request.
